Erlotinib for Hepatocellular Carcinoma Chemoprevention
Status:
Not yet recruiting
Trial end date:
2027-06-01
Target enrollment:
Participant gender:
Summary
This phase IIa trial studies long-term low-dose erlotinib hydrochloride treatment to assess
its efficacy and safety to prevent development of hepatocellular carcinoma in patients with
liver cirrhosis.